Cargando…

Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy

A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All...

Descripción completa

Detalles Bibliográficos
Autores principales: De Franceschi, Lucia, Castiglioni, Chiara, Condorelli, Claudia, Valsecchi, Diletta, Premoli, Eleonora, Fiocchi, Carina, Perrone, Valentina, Esposti, Luca Degli, Forni, Gian Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821386/
https://www.ncbi.nlm.nih.gov/pubmed/36614918
http://dx.doi.org/10.3390/jcm12010117
_version_ 1784865684858077184
author De Franceschi, Lucia
Castiglioni, Chiara
Condorelli, Claudia
Valsecchi, Diletta
Premoli, Eleonora
Fiocchi, Carina
Perrone, Valentina
Esposti, Luca Degli
Forni, Gian Luca
author_facet De Franceschi, Lucia
Castiglioni, Chiara
Condorelli, Claudia
Valsecchi, Diletta
Premoli, Eleonora
Fiocchi, Carina
Perrone, Valentina
Esposti, Luca Degli
Forni, Gian Luca
author_sort De Franceschi, Lucia
collection PubMed
description A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1–7.2% of patients were treated with SCD-specific, 58.4–69.4% with SCD-related, 60.7–71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient’ management and were most likely underestimated since indirect costs and Emergency Room admissions were not included.
format Online
Article
Text
id pubmed-9821386
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98213862023-01-07 Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy De Franceschi, Lucia Castiglioni, Chiara Condorelli, Claudia Valsecchi, Diletta Premoli, Eleonora Fiocchi, Carina Perrone, Valentina Esposti, Luca Degli Forni, Gian Luca J Clin Med Article A real-world analysis was conducted in Italy among sickle cell disease (SCD) patients to evaluate the epidemiology of SCD, describe patients’ characteristics and the therapeutic and economic burden. A retrospective analysis of administrative databases of various Italian entities was carried out. All patients with ≥1 hospitalization with SCD diagnosis were included from 01/2010-12/2017 (up to 12/2018 for epidemiologic analysis). The index date corresponded to the first SCD diagnosis. In 2018, SCD incidence rate was 0.93/100,000, the prevalence was estimated at 13.1/100,000. Overall, 1816 patients were included. During the 1st year of follow-up, 50.7% of patients had one all-cause hospitalization, 27.8% had 2, 10.4% had 3, and 11.1% had ≥4. Over follow-up, 6.1–7.2% of patients were treated with SCD-specific, 58.4–69.4% with SCD-related, 60.7–71.3% with SCD-complications-related drugs. Mean annual number per patient of overall treatments was 14.9 ± 13.9, hospitalizations 1.1 ± 1.1, and out-patient services 5.3 ± 7.6. The total mean direct cost per patient was EUR 7918/year (EUR 2201 drugs, EUR 3320 hospitalizations, and EUR 2397 out-patient services). The results from this real-world analysis showed a high disease burden for SCD patients with multiple hospitalizations during the follow-up. High healthcare resource utilization and costs were associated with patient’ management and were most likely underestimated since indirect costs and Emergency Room admissions were not included. MDPI 2022-12-23 /pmc/articles/PMC9821386/ /pubmed/36614918 http://dx.doi.org/10.3390/jcm12010117 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
De Franceschi, Lucia
Castiglioni, Chiara
Condorelli, Claudia
Valsecchi, Diletta
Premoli, Eleonora
Fiocchi, Carina
Perrone, Valentina
Esposti, Luca Degli
Forni, Gian Luca
Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title_full Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title_fullStr Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title_full_unstemmed Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title_short Real-World Evidence on Disease Burden and Economic Impact of Sickle Cell Disease in Italy
title_sort real-world evidence on disease burden and economic impact of sickle cell disease in italy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821386/
https://www.ncbi.nlm.nih.gov/pubmed/36614918
http://dx.doi.org/10.3390/jcm12010117
work_keys_str_mv AT defranceschilucia realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT castiglionichiara realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT condorelliclaudia realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT valsecchidiletta realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT premolieleonora realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT fiocchicarina realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT perronevalentina realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT espostilucadegli realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT fornigianluca realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly
AT realworldevidenceondiseaseburdenandeconomicimpactofsicklecelldiseaseinitaly